Clinical Trials Browser

Phase 3 × polatuzumab vedotin × 90 days × Clear all

NCT05171647 2026-03-06

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT03274492 2026-02-06

POLARIX

Phase 3 Active not recruiting

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse